Kuuno Vaher, market access director Baltics and country lead of AstraZeneca Estonia, discusses the liberal attitude towards innovative and highly needed medicines of Estonian regulators and the crucial importance of closer collaboration with payers, which has led the thriving affiliate to have its portfolio reimbursed in the country.
Can you begin by briefly walking our readers through AstraZeneca’s history in Estonia?
"The ease of market access and the overall process is significantly longer in Estonia than in countries like Sweden or Denmark, but it has worked out very well up until now."
